NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Lateral flow devices found to be useful in screening OUH staff for coronavirus

Lateral flow devices found to be useful in screening OUH staff for coronavirus

11 February 2021 · Listed under Antimicrobial Resistance and Modernising Microbiology, Clinical Informatics and Big Data, COVID-19

Infection prevention and control clinicians and researchers at Oxford University Hospitals (OUH) have been outlining the OUH’s experience of deploying self-administered home-based lateral flow testing of its staff.

Lateral flow device

In a letter published in the Journal of Infection, they said that 46,503 home-based SARS-CoV-2 lateral flow tests had been performed by asymptomatic OUH hospital staff. Of these, 328 (0.7%) were positive.

The positive predictive value of these tests (the probability that subjects with a positive screening test truly have the disease) was 96%, while the false positive rate was just 0.03%.

In line with NHSE/I guidance, lateral flow testing of nasal swabs for asymptomatic NHS staff was introduced for OUH staff based on all hospital sites. Staff are expected to test themselves with a home testing kit twice a week, every three to four days, to fit their shift patterns. Between 23 November 2020 and 9 January 2021, 8,657 healthcare workers and support staff had carried out LFD tests.

These tests are in addition to the Trust’s existing asymptomatic staff PCR testing programme where a test is offered a maximum of every two weeks..

While lateral flow devices (LFD) are less sensitive than PCR tests, they were found to be effective at detecting cases with high viral loads.

Dr Katie Jeffery, OUH Director Infection Prevention and Control, said: “This lateral flow testing system has been an important way for us to help reduce the spread of COVID-19 in our hospitals. We’d like to thank all the thousands of staff who have participated and reported their results.

“Use of LFDs identified asymptomatic SARS-CoV-2 infections that would not otherwise have been detected, allowing us to act to reduce staff-to-staff and staff-to-patient transmission. These staff had high viral loads, and were potentially highly infectious. Although individuals with low viral loads may be missed, with testing happening at least twice per week, those with early infection and rising viral loads are likely to be identified,” she explained.

Although some doubt has been cast on the sensitivity of LFDs when used by the general public, the experience at OUH in healthcare workers demonstrated the utility of the tests when performed on a regular basis in detecting asymptomatic cases allowing them to self-isolate and for contacts to be traced to protect the workforce and our patients..

The letter concluded that kit failure rates and false positive results in this cohort of healthcare workers and support staff were sufficiently low to support the widespread use of LFDs in asymptomatic populations.

Researchers involved in analysing the findings of the OUH staff testing programme are supported by the NIHR Oxford Biomedical Research Centre.

← Drug trial that could improve respiratory recovery from COVID-19 under way
Tocilizumab found to reduce deaths in hospitalised COVID-19patients →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre